Windtree Therapeutics Inc., of Warrington, Pa., received $700,000 grant under a previously awarded 2016 phase II Small Business Innovation Research grant valued at up to $2.6 million from the National Heart, Lung, and Blood Institute to support the Aerosurf phase IIb trial in premature infants 26 to 32 weeks gestational age receiving nasal continuous positive airway pressure for respiratory distress syndrome.